Finding the Genetic Cause of a Form of Hyperparathyroidism
Researchers have identified genetic differences that can cause familial isolated hyperparathyroidism. (Source: NIDDK News)
Source: NIDDK News - June 23, 2018 Category: Endocrinology Source Type: news
Cholecalciferol and Hyperparathyroidism Progression in CKD Cholecalciferol and Hyperparathyroidism Progression in CKD
A new study examines the effects of a higher dose of cholecalciferol on parathyroid hormone levels in patients with CKD.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
CDC73-Related Disorders in Primary Hyperparathyroidism CDC73-Related Disorders in Primary Hyperparathyroidism
This article provides insight into the clinical manifestations of CDC73-related disorders and discusses ways to improve case detection in primary hyperparathyroidism.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Parathyroidectomy No Better for Mild Primary Hyperparathyroidism
No reduction seen in mortality or key morbidities, including CV events, cerebrovascular events, cancer, peripheral fractures, kidney stones (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Nephrology, Oncology, Orthopedics, Surgery, Journal, Source Type: news
Amgen ’s Mimpara for secondary HPT children with ESRD receives marketing approval in EU
US-based biopharmaceutical company Amgen has been granted marketing authorisation by the European Commission (EC) for Mimpara (cinacalcet) to treat secondary hyperparathyroidism (HPT) in children with end ‑stage renal disease (ESRD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news
European Commission Approves Expanded Use Of Mimpara ® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., Aug. 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.
"Secondary HPT is a serious and complex condition, and there are currently limited treatment options available for pediatric patie...
Source: Amgen News Release - August 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated
Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 18, 2017 Category: Radiology Tags: Radiology News Source Type: news
The Often Missed Diagnosis of Primary Hyperparathyroidism The Often Missed Diagnosis of Primary Hyperparathyroidism
Dr Arefa Cassoobhoy highlights one of the week ' s important news stories for primary care.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 18, 2017 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news
Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia
Only a minority of patients with hypercalcemia are tested for hyperparathyroidism, and only a minority of those found to have hyperthyroidism receive surgical referrals, according to a new database study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 1, 2017 Category: Surgery Tags: General Surgery News Source Type: news
Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara ® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., June 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet). Approval was recommended for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.
"We are ple...
Source: Amgen News Release - June 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Thiazide Treatment in Primary Hyperparathyroidism Thiazide Treatment in Primary Hyperparathyroidism
Thiazides may be a safe and effective treatment alternative for patients with primary hyperparathyroidism when surgery is not an option.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Parathyroid Biopsy Extent Influences Gamma Probe Findings Parathyroid Biopsy Extent Influences Gamma Probe Findings
During radioguided surgery for hyperparathyroidism, a large proportion of hyperfunctional parathyroid gland must be evaluated to confirm complete excision of abnormal tissue via gamma probe, according to a retrospective review.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news
US FDA approves Amgen ’s Parsabiv to treat HPT in adult patients
The US Food and Drug Administration (FDA) has approved Amgen ’s Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 9, 2017 Category: Pharmaceuticals Source Type: news
FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism
The drug is the first approved in 12 years to treat secondary hyperparathyroidism in hemodialysis patients, and the first that can be given intravenously by a dialysis team.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 8, 2017 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news
FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2017 Category: Drugs & Pharmacology Source Type: news
